| 2024年中报 | 2023年年报 | 2023年中报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 草酸艾司西酞普兰片业务(元) | - | - | - | 2,125,500.00 |
| 原料药业务(元) | 181,914,375.98 | 351,811,465.32 | 171,340,814.12 | 163,213,500.00 |
| 中间体业务(元) | 22,253,143.30 | 34,558,649.75 | 17,344,129.79 | 42,802,800.00 |
| 制剂业务(元) | 5,409,497.31 | 7,992,363.76 | 2,766,415.83 | - |
| 其他业务(元) | - | - | - | 2,017,300.00 |
| 其他(元) | 1,059,828.50 | 3,090,791.03 | 1,916,660.89 | - |
| 营业成本(元) | ||||
| 草酸艾司西酞普兰片业务(元) | - | - | - | 1,069,900.00 |
| 原料药业务(元) | 108,617,015.13 | 207,276,764.42 | 104,419,647.71 | 107,050,400.00 |
| 中间体业务(元) | 12,093,480.13 | 19,790,906.61 | 11,166,329.63 | 21,381,900.00 |
| 制剂业务(元) | 2,095,523.28 | 3,642,236.60 | 928,110.03 | - |
| 其他业务(元) | - | - | - | 1,626,900.00 |
| 其他(元) | 1,549,903.54 | 3,474,914.43 | 1,474,633.98 | - |
| 毛利(元) | ||||
| 草酸艾司西酞普兰片业务(元) | - | - | - | 1,055,600.00 |
| 原料药业务(元) | 73,297,360.85 | 144,534,700.90 | 66,921,166.41 | 56,163,100.00 |
| 中间体业务(元) | 10,159,663.17 | 14,767,743.14 | 6,177,800.16 | 21,420,900.00 |
| 制剂业务(元) | 3,313,974.03 | 4,350,127.16 | 1,838,305.80 | - |
| 其他业务(元) | - | - | - | 390,400.00 |
| 其他(元) | -490,075.04 | -384,123.40 | 442,026.91 | - |
| 毛利率(%) | ||||
| 草酸艾司西酞普兰片业务(%) | - | - | - | 49.66 |
| 原料药业务(%) | 40.29 | 41.08 | 39.06 | 34.41 |
| 中间体业务(%) | 45.65 | 42.73 | 35.62 | 50.05 |
| 制剂业务(%) | 61.26 | 54.43 | 66.45 | - |
| 其他业务(%) | - | - | - | 19.35 |
| 其他(%) | -46.24 | -12.43 | 23.06 | - |
| 收入构成(%) | ||||
| 草酸艾司西酞普兰片业务(%) | - | - | - | 1.01 |
| 原料药业务(%) | 86.36 | 88.52 | 88.61 | 77.66 |
| 中间体业务(%) | 10.56 | 8.70 | 8.97 | 20.37 |
| 制剂业务(%) | 2.57 | 2.01 | 1.43 | - |
| 其他业务(%) | - | - | - | 0.96 |
| 其他(%) | 0.50 | 0.78 | 0.99 | - |
| 毛利构成(%) | ||||
| 草酸艾司西酞普兰片业务(%) | - | - | - | 1.34 |
| 原料药业务(%) | 84.95 | 88.53 | 88.78 | 71.07 |
| 中间体业务(%) | 11.78 | 9.05 | 8.20 | 27.10 |
| 制剂业务(%) | 3.84 | 2.66 | 2.44 | - |
| 其他业务(%) | - | - | - | 0.49 |
| 其他(%) | -0.57 | -0.24 | 0.59 | - |